(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian cancer. Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options … Continued
Four multidisciplinary teams to be funded to study survivorship (June 13, 2019) In a new collaboration, the American Cancer Society and Ovarian Cancer Research Alliance have joined forces to fund multidisciplinary research projects to explore new ways of detecting, treating, and preventing ovarian cancer relapse and for improving quality of life among those diagnosed with … Continued
OCRA is back from the American Society of Clinical Oncology’s annual meeting in Chicago, where doctors and researchers met to discuss the latest in the care of women with ovarian cancer. A few highlights: Progress is being made in the fight against ovarian cancer. Help keep research moving forward with your gift today.
(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer. Using data compiled by the Ovarian Cancer Association Consortium, researchers looked at the genetic profiles of around 25,000 women diagnosed with ovarian cancer and … Continued
(May 20, 2019) University of Chicago gynecologic oncologist Nita K. Lee wants the next generation of doctors to know that the story of ovarian cancer is changing for the better in small and meaningful ways. “I don’t want to sugarcoat this terrible disease, but I also want students to see that women are living longer,” … Continued
(April 3, 2019) In March, ovarian cancer researchers, clinicians and advocates gathered to attend the much-anticipated Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer, to discuss the latest cutting edge research. OCRA Research Advocate, Scientific Advisory Committee member, and ovarian cancer survivor Annie Ellis attended the meeting and wrote a report highlighting … Continued
(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers. The guidelines, a summary of which can be found here, have been updated after several studies were completed and the FDA approved several new drugs. The new guidelines address topics such as PARP … Continued
(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers. Phase 1 trials are used … Continued
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a history of successful breakthroughs, the program … Continued
(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the patient’s health. Now, doctors are rethinking that approach. The LION, Lymphadenectomy in Ovarian Neoplasms, trial … Continued
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued
(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer. Because mucinous patients don’t typically do particularly well on regimens usually used to treat the more common … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
